First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors

被引：1
|
作者：
Ku, G. [1 ]
Shen, L. [2 ]
Klempner, S. J. [3 ]
Pan, H. [4 ]
Kratz, J. [5 ]
Liang, X. [6 ]
Deng, Y. [7 ]
Kim, S. [8 ]
Wang, Z. [9 ]
Feller, L. [10 ]
Powderly, J. [11 ]
Dayyani, F. [12 ]
Schneider, R. E. [13 ]
Girda, E. [14 ]
Berlin, J. D. [15 ]
Spencer, K. [16 ]
Nguyen, M. T. [17 ]
Wang, V. [17 ]
Xu, C. [17 ]
Zhu, A. [18 ]
机构：
[1] MSKCC Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, New York, NY USA
[2] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China
[3] MGH Massachusetts Gen Hosp, Med Oncol Dept, Boston, MA USA
[4] Zhejiang Univ, Sir Run Run Run Shaw Hosp, Med, Sch Med, Hangzhou, Zhejiang, Peoples R China
[5] Univ Wisconsin, Med, Sch Med & Publ Hlth Med Phys, Madison, WI USA
[6] HuBei Canc Hosp, Med Dept, Wuhan, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 6, Med, Guangzhou, Guangdong, Peoples R China
[8] Univ Colorado, Med Oncol Dept, UCHlth Canc Care, Ctr Canc, Anschutz Med Campus, Aurora, CO USA
[9] China Med Univ, Med, Affiliated Hosp 1, Shenyang, Peoples R China
[10] Horizon BioAdvance, Med Oncol Dept, Lafayette, LA USA
[11] Carolina BioOncol Inst, Oncol, Huntersville, NC USA
[12] UCI Univ Calif Irvine, Med Dept, Hlth Manchester Pavil, Orange, CA USA
[13] Mary Crowley Canc Res Ctr, Med Oncol Dept, Dallas, TX USA
[14] Rutgers Canc Inst New Jersey, Med Oncol Dept, New Brunswick, NJ USA
[15] Vanderbilt Univ, Med Dept, Med Ctr, Preston Canc Res Bldg, Nashville, TN USA
[16] NYU, Med Dept, Langone Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
[17] I Mab Biopharma, Res & Dev, San Diego, CA USA
[18] I Mab Biopharma Co Ltd Headquarter, Res & Dev, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2178
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1039P
引用
收藏
页码：S631 / S631
页数：1
相关论文
共 50 条
  • [31] First-in-human study of IMAB362, an anti-claudin 18.2 monoclonal antibody, in patients with advanced gastroesophageal cancer
    Sahin, U.
    Schuler, M.
    Bauer, S.
    Krilova, A.
    Utsch, M.
    Huber, C.
    Tuereci, O.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] GEN1046 (Bispecific Antibody Targeting PD-L1 and 4-1BB): Preclinical Characteristics and Phase 1 Results in Solid Tumors
    Kunkel, Maria
    Muik, Alexander
    Altintas, Isil
    Gieseke, Friederike
    Schodel, Kristina
    Diken, Mustafa
    Sette, Angelica
    Stanganello, Eliana
    Vascotto, Fulvia
    Breij, Esther
    Sasser, Kate
    Tureci, Ozlem
    Forssmann, Ulf
    Ahmadi, Tahamtan
    Sahin, Ugur
    CANCER SCIENCE, 2023, 114 : 1566 - 1566
  • [33] First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors
    Papadopoulos, Kyriakos P.
    Harb, Wael
    Peer, Cody J.
    Hua, Qiong
    Xu, Siying
    Lu, Haolan
    Lu, Ni
    He, Yue
    Xu, Ting
    Dong, Ruiping
    Gong, John
    Liu, David
    ONCOLOGIST, 2021, 26 (09): : E1514 - E1525
  • [34] AM105: A novel bispecific antibody with Anti 4-1BB affibodies and EGFR antibody
    Kim, Dong-Wook
    Lee, Hyun-Jong
    Kim, Seong Yeol
    Yoon, Min
    Lee, Youngha
    Hwang, In-Sik
    Lee, Yoon
    Kim, Jong-Hoon
    Lee, Jong-Seo
    CANCER RESEARCH, 2024, 84 (06)
  • [35] First-in- class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study
    Bai, X.
    Chen, Y.
    Chen, Y.
    Liang, X.
    Wang, H.
    Sun, Y.
    Chu, Q.
    Pan, Y.
    Cui, J.
    Fang, J.
    Zhang, W.
    Xu, Q.
    Zhang, J.
    Liu, X.
    Dai, G.
    Kang, L.
    Li, N.
    Fang, M.
    Zhou, H.
    Liang, T.
    ANNALS OF ONCOLOGY, 2024, 35 (07) : 681 - 682
  • [36] First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors
    Elena Elez, Maria
    Tabernero, Josep
    Geary, David
    Macarulla, Teresa
    Kang, S. Peter
    Kahatt, Carmen
    Soto-Matos Pita, Arturo
    Fernandez Teruel, Carlos
    Siguero, Mariano
    Cullell-Young, Martin
    Szyldergemajn, Sergio
    Ratain, Mark J.
    CLINICAL CANCER RESEARCH, 2014, 20 (08) : 2205 - 2214
  • [37] A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors
    Koganemaru, S.
    Yoshizuka, N.
    Mizuno, S.
    Hirai, S.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S531 - S531
  • [38] First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours
    Melero, I.
    Sanmamed, M. F.
    Calvo, E.
    Moreno, I.
    Moreno, V.
    Hernandez Guerrero, T. C.
    Martinez-Garcia, M.
    Rodriguez-Vida, A.
    Tabernero, J.
    Azaro Pedrazzoli, A. B.
    Spanggaard, I.
    Rohrberg, K. S.
    Guarin, E.
    Nueesch, E.
    Chesne, E.
    Ceppi, M.
    Sweere, U.
    McIntyre, C.
    Lichtenegger, F. S.
    Krieter, O.
    ANNALS OF ONCOLOGY, 2020, 31 : S707 - S707
  • [39] Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001).
    Henry, Jason Timothy
    Mehnert, Janice M.
    Rudnicki, Erika
    Pinelli, Juan
    Daud, Adil
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors
    Oh, Do-Youn
    Lee, Keun-Wook
    Han, Sae-Won
    Kim, Jin Won
    Shin, Jung-Won
    Jo, Seong-Jin
    Won, Jonghwa
    Hahn, Seokyung
    Lee, Howard
    Kim, Woo Ho
    Bang, Yung-Jue
    ONCOLOGIST, 2019, 24 (08): : 1037 - +
12345